PORTLAND-- Women with the most aggressive form of breast cancer are getting some new hope from research done right here in Portland.
Women with triple negative breast cancer don't usually respond to the most traditional therapies. The prognosis is also another five to eight years to live, but this new research is aiming at extending that.
Scientists at Oregon Health & Science University have discovered a drug, PLX 3397, that helps boost immune cells. It then helps a new form of chemotherapy, Arubalin, do its job. The hope? Eventually cancers like triple negative will become a lifelong chronic disease and not a life ender.
"Really anyone has been affected by cancer, either with a loved one or themselves, so the faster we get this done, the more people we're helping," said post-doctoral fellow Brian Ruffell.
It's with that urgency OHSU researchers are doing clinical trials for these women. Thanks to a $7 million grant from Susan G. Komen breast cancer foundation, they’re doing these trials in real time. Meaning, as they test this immune boosting drug and they notice side effects or something isn't working, they can come back to the labs at OHSU, tweak the program and hopefully extend the lives of the patients.
Usually, researchers have to wait until the trial is over before they make any changes.
The clinical trials number in 503-494-1080 or you can email them at email@example.com.